Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death

INTRODUCTION: Platinum-based chemotherapy remains the standard treatment for patients with small cell lung cancer (SCLC), but the benefit of the treatment is often hampered by rapid development of drug resistance. Thus far, there is no targeted therapy available for SCLC. Over 90% of SCLC tumors har...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Thorac Oncol
Auteurs principaux: Hsu, Wei-Hsun, Zhao, Xiaoliang, Zhu, Jianquan, Kim, In-Kyu, Rao, Guanhua, McCutcheon, Justine, Hsu, Shuo-Tse, Teicher, Beverly, Kallakury, Bhaskar, Dowlati, Afshin, Zhang, Yu-Wen, Giaccone, Giuseppe
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534433/
https://ncbi.nlm.nih.gov/pubmed/30771522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.01.028
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires